Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Affymax's Peginesatide May Be Tough Sell To ODAC As ESAs Cast Long Showdow

This article was originally published in The Pink Sheet Daily

Executive Summary

Safety concerns over erythropoiesis-stimulating agents seem to extend to Affymax's peginesatide, and since it lacks an efficacy edges over these drugs in treating anemia due to chronic kidney disease, an approval basis is unclear.


Related Content

Kidney Disease: A Price-Sensitive Market But A Bundle Of Opportunity
ESRD Market Snapshot: The Price Has To Be Right
Affymax Anticipates Broad Opportunity For Omontys With Both Small And Large Dialysis Providers
Affymax Once-Monthly ESA Will Target Smaller Dialysis Centers
Off-Label Safety Signal For Affymax's Peginesatide Doesn't Dissuade ODAC, With Assurance Of Restricted Distribution
ApoPharma's Preemptive Safety Strategy For Ferriprox Includes Centralized Pharmacy Distribution
Affymax Plans For Peginesatide Launch
FDA Draws Upon New Authority To Mandate Elements OF ESA Labeling


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts